The Spanish health ministry is consulting on a draft royal decree to update and clarify key aspects of existing regulation for setting prices and financing medicines available on the national health system (SNS). Measures proposed include the possibility of reviewing prices of medicines that are already reimbursed and establishing criteria for authorizing accelerated reimbursement.
Spanish Health Ministry Targets Efficiency With New Medicine Pricing Rules
A draft royal decree would pave the way for more transparency in pricing and reimbursement decision-making processes and boost competition to increase the participation of generic medicines.
More from Spain
• By
The first reimbursement reports published by the Spanish health ministry to improve transparency focus on CSL’s Hemgenix, BMS’ Camzyos and Pfizer’s Velsipity.
• By
CSL Behring explains how it worked with authorities in Denmark, Austria, England, Scotland, Spain and Switzerland to secure innovative access arrangements suitable to each nation’s “unique needs” for its one-time gene therapy, Hemgenix.
• By
The strategy includes a committee made up of pharmaceutical industry representatives and ministers to discuss the impact of regulatory proposals.
• By
A draft royal decree would pave the way for more transparency in pricing and reimbursement decision-making processes and boost competition to increase the participation of generic medicines.
More from Market Access
• By
Cell and gene therapy manufacturers must consider the practicalities of their product within the context of a health care system before it comes onto the market to be successful, experts from Novartis, AstraZeneca and England’s National Health Service say.
• By
Democrats opposed the nomination because they believe Mehmet Oz will not defend Medicaid from spending cuts. His pledge to continue lowering drug costs in Medicare and Medicaid did not offset the concerns.
• By
An analysis of Medicare Part D and other data found that more than one-third of all pharmacy spending went through pharmacies owned by Cigna, CVS Health, Humana or UnitedHealth Group.